Protective immunity induced by phage displayed mitochondrial related peptides of Schistosoma japonicum

Wu, Hongxun; Hu, Xuemei; Wang, Yong; Kurtis, Jonathan D.; Zeng, Fan-Jie; McGarvey, Stephen T.; Wu, Guan-Ling; Zhang, Zhao-Song; Zhang, Hua

doi:10.1016/j.actatropica.2006.08.006

Cited by 26 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One could speculate that a major requirement for a successful vaccine will be based not only on the most effective way of inducing immunity, but also on the technical feasibility of its production [57] . Phage-displayed peptides as candidates possess two main advantages: first, peptides exposed in filamentous phages are antigenic and immunogenic.…”

Section: Discussionmentioning

confidence: 99%

Mimotope-Based Vaccines of Leishmania infantum Antigens and Their Protective Efficacy against Visceral Leishmaniasis

et al. 2014

View full text Add to dashboard Cite

BackgroundThe development of cost-effective prophylactic strategies to prevent leishmaniasis has become a high-priority. The present study has used the phage display technology to identify new immunogens, which were evaluated as vaccines in the murine model of visceral leishmaniasis (VL). Epitope-based immunogens, represented by phage-fused peptides that mimic Leishmania infantum antigens, were selected according to their affinity to antibodies from asymptomatic and symptomatic VL dogs' sera.Methodology/Main FindingsTwenty phage clones were selected after three selection cycles, and were evaluated by means of in vitro assays of the immune stimulation of spleen cells derived from naive and chronically infected with L. infantum BALB/c mice. Clones that were able to induce specific Th1 immune response, represented by high levels of IFN-γ and low levels of IL-4 were selected, and based on their selectivity and specificity, two clones, namely B10 and C01, were further employed in the vaccination protocols. BALB/c mice vaccinated with clones plus saponin showed both a high and specific production of IFN-γ, IL-12, and GM-CSF after in vitro stimulation with individual clones or L. infantum extracts. Additionally, these animals, when compared to control groups (saline, saponin, wild-type phage plus saponin, or non-relevant phage clone plus saponin), showed significant reductions in the parasite burden in the liver, spleen, bone marrow, and paws' draining lymph nodes. Protection was associated with an IL-12-dependent production of IFN-γ, mainly by CD8+ T cells, against parasite proteins. These animals also presented decreased parasite-mediated IL-4 and IL-10 responses, and increased levels of parasite-specific IgG2a antibodies.Conclusions/SignificanceThis study describes two phage clones that mimic L. infantum antigens, which were directly used as immunogens in vaccines and presented Th1-type immune responses, and that significantly reduced the parasite burden. This is the first study that describes phage-displayed peptides as successful immunogens in vaccine formulations against VL.

show abstract

Section: Discussionmentioning

confidence: 99%

Mimotope-Based Vaccines of Leishmania infantum Antigens and Their Protective Efficacy against Visceral Leishmaniasis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This is a parasitic infection that primarily infects humans and pigs in Mexico and other Latin American countries and is characterized by headaches and seizures when infection is localized to the nervous system 106. Potential vaccine candidates have also been identified for Schistosoma japonicum infection, which infects humans and other wild mammals with a chronic illness that can damage internal organs 107. An effective vaccine is important in this case because there is little natural immunity to reinfection.…”

Section: Display Of Heterologous Epitopes On Plant Virusesmentioning

confidence: 99%

Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design

Plummer

Manchester

2010

WIREs Nanomed Nanobiotechnol

205

217

View full text Add to dashboard Cite

Current vaccines that provide protection against infectious diseases have primarily relied on attenuated or inactivated pathogens. Virus-like particles (VLPs), comprised of capsid proteins that can initiate an immune response but do not include the genetic material required for replication, promote immunogenicity and have been developed and approved as vaccines in some cases. In addition, many of these VLPs can be used as molecular platforms for genetic fusion or chemical attachment of heterologous antigenic epitopes. This approach has been shown to provide protective immunity against the foreign epitopes in many cases. A variety of VLPs and virus-based nanoparticles are being developed for use as vaccines and epitope platforms. These particles have the potential to increase efficacy of current vaccines as well as treat diseases for which no effective vaccines are available.

show abstract

“…The greatest advantage of identifying epitopes by screening random peptide libraries is that it is not necessary to know the site of the antigen recognized by the antibody [27]. So far, many antigenic epitopes have been identified using this technology [28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Selection of high affinity peptide ligands for detection of circulating antibodies in neurocysticercosis

et al. 2010

View full text Add to dashboard Cite

Protective immunity induced by phage displayed mitochondrial related peptides of Schistosoma japonicum

Cited by 26 publications

References 28 publications

Mimotope-Based Vaccines of Leishmania infantum Antigens and Their Protective Efficacy against Visceral Leishmaniasis

Mimotope-Based Vaccines of Leishmania infantum Antigens and Their Protective Efficacy against Visceral Leishmaniasis

Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design

Selection of high affinity peptide ligands for detection of circulating antibodies in neurocysticercosis

Contact Info

Product

Resources

About